CELLphenomics and Charles River Laboratories International announced an agreement that provides Charles River clients with access to CELLphenomics’ proprietary 3D tumour model platform, PD3D, which will expand Charles River’s 3D in vitro testing services to further optimise oncological approaches for its clients.
CELLphenomics’ core competence is the establishment and cultivation of complex patient-derived 3D cell culture models (PD3D) from various solid tumour tissues.
These highly reliable and predictive preclinical PD3D models robustly recapitulate the biological properties of the donor tissue, including key histopathological features and genomic makeup.
They are a powerful tool for disease modelling, biomarker and drug discovery. CELLphenomics’ continuously growing biobank comprises more than 500 complex in vitro models from more than 20 tumour entities and offers the world’s largest collection of complex in vitro models of rare and ultra-rare tumours such as sarcomas or thymomas.
CELLphenomics has developed a custom high-throughput screening platform that blends complex cell culture models with advanced automation and a streamlined analysis pipeline.
The proprietary precision medicine PD3D platform offers high-throughput efficacy testing, drug combination screening, toxicity profiling, target validation, drug sensitivity correlation with clinical response and biomarker identification.
Charles River offers a range of cancer cell-based assays, including patient-derived xenograft (PDX) assays and assays representing the entire tumour microenvironment (TME), so therapies are not only tested for their effect on real patient materials, but also their interaction with the human immune systems.
Leveraging CELLphenomics technology, Charles River will now have a novel in vitro option to identify therapeutics for rare and ultra-rare disease types.
The agreement will also provide CELLphenomics access to Charles River’s genomically annotated and in vivo characterised cancer model database. The database is comprised of more than 700 tumour models, including PDX, cell lines and cell line derived xenografts (CDX).
These models have been extensively profiled for histological features, molecular data and sensitivity to standard-of-care compounds, allowing a precise selection of suitable tumour models for preclinical anticancer agent testing.
The biological advantages of PDX include the retention of histological and genetic characteristics of the donor tumour and the preservation of cell-autonomous heterogeneity.
The merge of both biobanks will significantly increase the translational relevance of the in vitro and the in vivo platforms offered by CELLphenomics and Charles River.
